The Combined General Meeting will be held on second call

Biophytis strengthens its financial position and extends its cash runway into Q1 2027

31 August 2026

Cash position strengthened to €3.0 million Most 2026 share warrants exercised Phase 2 study in obesity to start in Q1 2027 Hong-Kong JV to start operations for preparing Phase 3…

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY

10 August 2026

Biophytis today announces that it has received approval from Brazil’s National Health Surveillance Agency (ANVISA) to begin the Phase 2 OBA clinical trial for obesity in Brazil and shares the…

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE

3 August 2026

Biophytis provides an update on the rollout of its joint venture in Hong Kong (see details in the “About” section below) and shares its short- and medium-term outlook. Landmark milestones…

Biophytis announces the auditing of its 2025 financial statements and the resumption of trading in its stock

29 July 2026

Biophytis announces the publication of its parent company financial statements for the fiscal year ended December 31, 2025, prepared in accordance with French accounting rules and principles and approved by…

BIOPHYTIS REPORTS ITS PROVISIONAL FINANCIAL RESULTS AND PROVIDES ITS STRATEGIC OUTLOOK

1 July 2026

Biophytis reports its provisional, unaudited financial results for the fiscal year 2025 and provides an update on its strategic outlook.

BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES

15 June 2026

Biophytis announces the temporary suspension of trading in its shares on Euronext. This suspension follows the failure to publish the annual financial report for the fiscal year ended December 31,…

The Combined General Meeting will be held on second call on April 17, 2023